Arrowhead Pharmaceuticals Inc. [NASDAQ: ARWR] gained 5.01% on the last trading session, reaching $43.80 price per share at the time.
Arrowhead Pharmaceuticals Inc. represents 101.84 million in outstanding shares, while the company has a total market value of $4.76 billion with the latest information. ARWR stock price has been found in the range of $41.60 to $44.10.
If compared to the average trading volume of 1.45M shares, ARWR reached a trading volume of 1419762 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Arrowhead Pharmaceuticals Inc. [ARWR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARWR shares is $64.45 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARWR stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Arrowhead Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 13, 2020. The new note on the price target was released on May 08, 2020, representing the official price target for Arrowhead Pharmaceuticals Inc. stock. Previously, the target price had yet another raise from $55 to $60, while Cantor Fitzgerald kept a Overweight rating on ARWR stock.
The Average True Range (ATR) for Arrowhead Pharmaceuticals Inc. is set at 3.42, with the Price to Sales ratio for ARWR stock in the period of the last 12 months amounting to 38.45. The Price to Book ratio for the last quarter was 9.05, with the Price to Cash per share for the same quarter was set at 2.64.
Trading performance analysis for ARWR stock
Arrowhead Pharmaceuticals Inc. [ARWR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 29.59. With this latest performance, ARWR shares gained by 3.08% in over the last four-week period, additionally plugging by 52.99% over the last 6 months – not to mention a rise of 51.66% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARWR stock in for the last two-week period is set at 55.27, with the RSI for the last a single of trading hit 59.00, and the three-weeks RSI is set at 54.21 for Arrowhead Pharmaceuticals Inc. [ARWR]. The present Moving Average for the last 50 days of trading for this stock 42.81, while it was recorded at 44.36 for the last single week of trading, and 41.73 for the last 200 days.
Arrowhead Pharmaceuticals Inc. [ARWR]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Arrowhead Pharmaceuticals Inc. [ARWR] shares currently have an operating margin of +36.25. Arrowhead Pharmaceuticals Inc.’s Net Margin is presently recorded at +40.27.
Return on Total Capital for ARWR is now 35.83, given the latest momentum, and Return on Invested Capital for the company is 39.69. Return on Equity for this stock inclined to 39.94, with Return on Assets sitting at 29.46.
Reflecting on the efficiency of the workforce at the company, Arrowhead Pharmaceuticals Inc. [ARWR] managed to generate an average of $507,275 per employee. Receivables Turnover for the company is 341.44 with a Total Asset Turnover recorded at a value of 0.73.Arrowhead Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.40 and a Current Ratio set at 7.40.
Arrowhead Pharmaceuticals Inc. [ARWR]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Arrowhead Pharmaceuticals Inc. posted 0.11/share EPS, while the average EPS was predicted by analysts to be reported at 0.16/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -31.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ARWR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Arrowhead Pharmaceuticals Inc. go to 7.33%.
An analysis of insider ownership at Arrowhead Pharmaceuticals Inc. [ARWR]
There are presently around $3,022 million, or 67.70% of ARWR stock, in the hands of institutional investors. The top three institutional holders of ARWR stocks are: BLACKROCK INC. with ownership of 12,954,928, which is approximately 4.21% of the company’s market cap and around 3.70% of the total institutional ownership; VANGUARD GROUP INC, holding 9,719,363 shares of the stock with an approximate value of $425.71 million in ARWR stocks shares; and STATE STREET CORP, currently with $214.25 million in ARWR stock with ownership of nearly 13.896% of the company’s market capitalization.
Positions in Arrowhead Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 144 institutional holders increased their position in Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] by around 8,181,561 shares. Additionally, 111 investors decreased positions by around 4,670,374 shares, while 38 investors held positions by with 56,148,901 shares. The mentioned changes placed institutional holdings at 69,000,836 shares, according to the latest SEC report filing. ARWR stock had 42 new institutional investments in for a total of 4,136,194 shares, while 35 institutional investors sold positions of 1,749,588 shares during the same period.